- Home
- APEI vs TCRX Comparison
APEI vs TCRX Comparison
Compare APEI & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APEI
- TCRX
- Stock Information
- Founded
- APEI 1991
- TCRX 2018
- Country
- APEI United States
- TCRX United States
- Employees
- APEI N/A
- TCRX N/A
- Industry
- APEI Other Consumer Services
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- APEI Consumer Discretionary
- TCRX Health Care
- Exchange
- APEI Nasdaq
- TCRX Nasdaq
- Market Cap
- APEI 253.0M
- TCRX 257.5M
- IPO Year
- APEI 2007
- TCRX 2021
- Fundamental
- Price
- APEI $21.15
- TCRX $2.90
- Analyst Decision
- APEI Buy
- TCRX Strong Buy
- Analyst Count
- APEI 4
- TCRX 5
- Target Price
- APEI $21.00
- TCRX $11.40
- AVG Volume (30 Days)
- APEI 94.3K
- TCRX 447.2K
- Earning Date
- APEI 11-12-2024
- TCRX 11-12-2024
- Dividend Yield
- APEI N/A
- TCRX N/A
- EPS Growth
- APEI N/A
- TCRX N/A
- EPS
- APEI 0.56
- TCRX N/A
- Revenue
- APEI $613,253,000.00
- TCRX $9,362,000.00
- Revenue This Year
- APEI $5.70
- TCRX N/A
- Revenue Next Year
- APEI $3.90
- TCRX $4.11
- P/E Ratio
- APEI $37.95
- TCRX N/A
- Revenue Growth
- APEI 2.18
- TCRX N/A
- 52 Week Low
- APEI $8.50
- TCRX $2.60
- 52 Week High
- APEI $23.84
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- APEI 56.48
- TCRX 29.33
- Support Level
- APEI $21.55
- TCRX $2.82
- Resistance Level
- APEI $23.84
- TCRX $3.15
- Average True Range (ATR)
- APEI 0.93
- TCRX 0.41
- MACD
- APEI -0.09
- TCRX -0.13
- Stochastic Oscillator
- APEI 22.92
- TCRX 12.82
About APEI American Public Education Inc.
American Public Education Inc provides online and on-campus postsecondary education including various undergraduate and graduate degree programs. The fields of study include business administration, health science, technology, criminal justice, education, liberal arts, national security, military studies, intelligence, and homeland security. There are three reporting segments: the American Public University segment which is the key revenue generator; the Rasmussen University Segment and the Hondros College of Nursing segment. The revenue is generated from net course registrations and enrollment, tuition rate, net tuition, and other fees.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.